On January 7, 2022 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported that it will present data on Iovance tumor-infiltrating lymphocyte (TIL) cell therapy at the upcoming Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, to be held February 2 – 6, 2022 in Salt Lake City, Utah, and virtually (Press release, Iovance Biotherapeutics, JAN 7, 2022, View Source [SID1234598409]). Details for the abstracts are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia
Presenting Author: Anandaraman Veerapathran, Iovance Biotherapeutics
Presentation Type: Poster
Abstract ID: 287

Title: Decitabine Treatment of Tumor-Infiltrating Lymphocytes (TIL) during Ex Vivo Expansion Induces a More Memory-like Phenotype, Reduces Inhibitory Receptor Expression, and Increases Functionality
Presenting Author: Rafael Cubas, Iovance Biotherapeutics
Presentation Type: Poster
Abstract ID: 270

Poster Display Hours: Wednesday, February 2, 2022 from 10:00 am to 8:00 pm; Thursday, February 3, 2022 from 7:00 am to 8:15 pm; Friday, February 4, 2022 from 7:00 am to 8:00 pm; and Saturday, February 5, 2022 from 7:00 am to 7:45 pm (all times MST)

Poster Receptions: Thursday, February 3, 2022 from 6:45 pm to 8:15 pm MST and Saturday, February 5, 2022 from 6:15 pm to 7:45 pm MST